Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 144(1), P. e10 - e12
Published: June 20, 2024
Language: Английский
Women & Health, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15
Published: Jan. 17, 2025
A growing body of evidence suggests a potential link between the SARS-CoV-2 vaccine and menstrual changes in women who were menstruating at time vaccination. Nevertheless, prevalence this event those with secondary amenorrhea for different causes, i.e. formerly women, remains unclear. It is plausible that, analogous to observed currently they experienced some degree alteration their reproductive health, defined here as menstrual-related disturbances. The aim was analyze phenomenon identify factors associated occurrence disturbances subpopulation. Study design: retrospective observational cross-sectional study conducted among adult Spanish December 2021 using an online survey (N = 17,512). present analysis includes subpopulation vaccinated 548). General characteristics, medical history, adverse events following COVID-19 vaccination recorded. Chi-square, Mann-Whitney U McNemar mid-P tests performed. Bivariate logistic regression then used key influencing unexpected event. In comparison first dose, significantly higher percentages respondents (dose 1: 38.5 percent vs. dose 2: 44.8 percent) after receiving second one. Among them, related length flow stand out, being long-term nature about 17-20 cases. Interindividual 1 may include weight, perimenopause, preexisting diagnoses non-autoimmune rheumatic/articular conditions, use hormonal contraceptives, suffering from other side effects - such arm pain number previous pregnancies; 2, these alterations 1, well contraceptives perimenopause. Formerly might experience Potential pregnancies.
Language: Английский
Citations
0
The Pediatric Infectious Disease Journal, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 28, 2025
Background: The COVID-19 pandemic’s transition to an endemic phase emphasizes the importance of vaccination. Despite initial strong immunogenicity, waning vaccine-induced immunity requires further investigation. Therefore, this study evaluated immunogenicity BNT162b2 vaccine in adolescents, focusing on spike-specific and neutralizing antibody kinetics following primary booster vaccinations as well impact breakthrough infections. Methods: This observational included 157 adolescents 12–17 years old who received 22 participants doses. Antibody levels were measured at 1, 3, 5 10 months post-vaccination post-booster. Breakthrough infections identified using SARS-CoV-2 antigen/polymerase chain reaction tests. Safety was monitored by tracking adverse effects. Results: Post-primary vaccination, geometric mean titer anti-spike antibodies decreased significantly over time, with a 2.3-fold reduction after months. Booster doses induced higher titers, which also waned albeit more slowly. boosted including those against variants such Delta Omicron. Long-term effects minimal, only 7 cases transient lymph node enlargement menstrual irregularities. Conclusions: robust immune responses adolescents; however, time. are essential for sustained protection, especially emerging variants. enhance responses, highlighting benefits hybrid immunity. safety profile is generally favorable; ongoing monitoring warranted.
Language: Английский
Citations
0
BMC Women s Health, Journal Year: 2024, Volume and Issue: 24(1)
Published: Sept. 19, 2024
Language: Английский
Citations
1
International Journal of Environmental Research and Public Health, Journal Year: 2024, Volume and Issue: 21(8), P. 1090 - 1090
Published: Aug. 18, 2024
During the rapid development of COVID-19 vaccines, concerns emerged about potential adverse effects on menstrual health. This study examines association between vaccination-considering number doses and vaccine type-and disorders, specifically heavy bleeding (HMB) amenorrhea (AM). Utilizing electronic health records from Sistema d'Informació per al Desenvolupament de la Investigació en Atenció Primària (SIDIAP) database in Catalonia, Spain, retrospective cohort included 1,172,621 vaccinated women aged 12-55 with no prior disorders observed 27 December 2020 to 30 June 2023. The incidence rate HMB AM increased second third vaccine. Notably, AstraZeneca
Language: Английский
Citations
0
Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 144(1), P. e12 - e13
Published: June 20, 2024
Citations
0
Obstetrics and Gynecology, Journal Year: 2024, Volume and Issue: 144(1), P. e10 - e12
Published: June 20, 2024
Language: Английский
Citations
0